Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Complement 5a Receptor (C5aR), also known as CD88 or C5AR1, is a G protein-coupled receptor that binds the complement component C5a. It is widely expressed on immune cells and mediates many of the pro-inflammatory effects of C5a, including chemotaxis, cytokine secretion, and phagocytosis. C5aR activation leads to downstream signaling through Gαi proteins, ERK1/2 phosphorylation, calcium mobilization, and Rho activation. Because excessive complement activation contributes to various diseases, C5aR is an attractive drug target for anti-inflammatory therapies, particularly for autoimmune disorders and transplant rejection. Antagonists, including small molecules and monoclonal antibodies, are being developed to block receptor function and reduce inflammation.
Selective inhibition of pro-inflammatory signaling by blocking C5a binding and downstream signaling pathways (e.g., Gαi, ERK1/2, calcium mobilization, Rho activation)
3 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Complement 5a Receptor (C5aR).